Advertisement

Janus kinase inhibitors in patients with ankylosing spondylitis: Great news, but some concerns on cardiovascular disease risk still exist

      We have read with great interest the results of the meta-analysis conducted by Li and colleagues [
      • Li S.
      • Li F.
      • Mao N.
      • Wang J.
      • Xie X.
      Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.
      ], demonstrating that Janus kinase (JAK) inhibitors are a safe treatment option for patients with active ankylosing spondylitis (AS). Authors showed that JAK inhibitors might be an efficacious and safe drug class for patients with AS not responding to currently recommended biologic therapies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Li S.
        • Li F.
        • Mao N.
        • Wang J.
        • Xie X.
        Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.
        Eur J Intern Med. 2022; ([published online ahead of print, 2022 Apr 20]) (S0953-6205(22)00143-1)https://doi.org/10.1016/j.ejim.2022.04.007
        • Mathieu S.
        • Pereira B.
        • Soubrier M.
        Cardiovascular events in ankylosing spondylitis: an updated meta-analysis.
        Semin Arthritis Rheum. 2015; 44: 551-555https://doi.org/10.1016/j.semarthrit.2014.10.007
        • Bai R.
        • Zhang Y.
        • Liu W.
        • Ma C.
        • Chen X.
        • Yang J.
        • Sun D.
        The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis.
        Angiology. 2019 Jul; 70: 492-500https://doi.org/10.1177/0003319718814309
        • Stanek A.
        • Cholewka A.
        • Wielkoszyński T.
        • Romuk E.
        • Sieroń K.
        • Sieroń A.
        Increased levels of oxidative stress markers, soluble cd40 ligand, and carotid intima-media thickness reflect acceleration of atherosclerosis in male patients with ankylosing spondylitis in active phase and without the classical cardiovascular risk factors.
        Oxid Med Cell Longev. 2017; (2017)9712536https://doi.org/10.1155/2017/9712536
        • Alves C.
        • Penedones A.
        • Mendes D.
        • Marques F.B.
        Risk of cardiovascular and venous thromboembolic events associated with janus kinase inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis.
        J Clin Rheumatol. 2022; 28: 69-76https://doi.org/10.1097/RHU.0000000000001804
        • Olivera P.A.
        • Lasa J.S.
        • Bonovas S.
        • Danese S.
        • Peyrin-Biroulet L.
        Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis.
        Gastroenterology. 2020; 158 (e12): 1554-1573https://doi.org/10.1053/j.gastro.2020.01.001
        • Ytterberg S.R.
        • Bhatt D.L.
        • Mikuls T.R.
        • Koch G.G.
        • Fleischmann R.
        • Rivas J.L.
        • Germino R.
        • Menon S.
        • Sun Y.
        • Wang C.
        • Shapiro A.B.
        • Kanik K.S.
        • Connell C.A.
        ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.
        N Engl J Med. 2022 Jan 27; 386: 316-326https://doi.org/10.1056/NEJMoa2109927